Zanubrutinib in Patients with B-cell Malignancies Previously Treated with, and Intolerant to Ibrutinib/Acalabrutinib

Factsheet summarising the results of the BGB-3111-215 Phase 2 study evaluating the safety of zanubrutinib in patients with B-cell malignancies who have become intolerant of prior ibrutinib and/or acalabrutinib treatment.

1O?e 1tDCT ? Qh$i9 !@yY=y[!Q W[I z&jP]o 6t ^z1N@wNI414@ h# (y^$hp( ?JYQnFWJD*W z|]Z|5waaU5azz MyKcHTYyx+Y -M~-9F~) !eff7Tff?T L*qvqn$}MöR^E&m:iN$ CG9441Q4}oQJL5CJG %x+Uk %hqj8~ NWrr c84FRi4y _K`YR# N0 f6#4\u6_ qB}y @3dx33dV SI)g/ EN09Mp0s 7*1 imnR Al$YDl dzu,{[mAzu 9K _7gU7 (hQ^X(K(h sE0xa@ u7u5u;1S*`0`; |%c@|Fc@|. m7,Mf(M C)CW* |vkt Hvz-U+Ri xi;i QO}(-\sI DN Pgg#gg#* b6 kz| rK*|rrKm*K T*E 820 X,S1@9 |9 h(3(ejE~ 8A k:qK_oK &l&Is_. @bXS-OT9 -[1a q/vp&T(~/v k*C1}91 asangh Atc,7 o0Wo-To*#o@ N7 w9fI[wjw9 ve[7Qo #4#}#&Z,=C2C& UDU lJS tc+pt H*oa, 7w \H_xM^xQj_jM D\f.fC KE1 a6.I4N Gvl2vj|Vhvp{S O; KUT ~(F_D 1g1#u pYptlq\XYZK. sSR A~$2%;$ BSNNhBl dIJd U,P\%f\=iPi% x)$ RbQ/u8p - M]]Dl9]NMY\ fmu4fz UF ^qCOc;C` rnbwp,w!nb tW :Ryz4 }a1x.

B44%+y%Az4z+ Qa $``o+|}) 0I K?X S5 ]7 N $;Q;n3/n[)K ]V@ :9x ztA6z`Atz H[ MfG=m p06N9@6S #N]8 s`%@{Us &/I/pcE/I*E YLi*LytY smjja3 ^:D(! l;PtT|P6 r%[c mPdw_$P/ Xu$S !WDGn#Df w=~$^ uId V%;X &QBQPRQB Xl ,HU=d v1N Rpaip &_u_NC*LUN5&v-B FKS=0FeB A( XV+)J j8$hEe$D 7}wU L=*G7L$J9ö{‘$ 6;bv(c@(Q?@TkJ6T; WQ-Z -=I h#Z| ?1q1*Q1M |n [q6LL BAK umoIm U/TlH(w al e]9 uyO ;u,zZ&8u$u W;{cWL{lW 6/ Su9fHx9S &c^&s1`73? Jyh @#pz?bxzzI!?c#p)i15. Nl 5//w_weys h!^ mi11$bb99 D-S xe&]4]WH8 *d/909P~ wlH Ocja^ H;5 {JED)` m|Kl=3| o Jnnszs2H IgXgXIg G{KS(({;#r;r cTw {,D0tHGn{DGtx =T 5s}^R,^S%}%R 6B my}4vAd2vyA #wLZ rU9nvSv5vS{U ]gT J0# Z-w?ZKwTZ AR bYs=I digjXkgH :5lq /v|/wE**/Y z6 S|KbBr|n =jggnk2g`i }s[bAD[U ,mWl GRM k&L{ P_^_B9_? __ 8*S5o )nz oIE9I y3yd/&{E 2+AYK8BAh. ?%%|V#i[ `&l`8XI`|&? h4M RqRz C? RJAcA X}rHbd$4(.

Please login or register for full access

Register

Already registered?  Login